文献速递临床试验与 GCP真实世界研究与卫生经济

电子尼古丁装置辅助酒精及药物依赖者戒烟:一项预试验随机对照试验方案

Electronic nicotine devices to aid smoking cessation by alcohol- and drug-dependent clients: protocol for a pilot randomised controlled trial.
PubMed 文献 · Trials · 2018-08-02

该方案计划在澳大利亚墨尔本一家无烟住宅戒断服务机构招募100名酒精或药物依赖者,出院前随机分为电子尼古丁装置组(n=50)与联合尼古丁替代疗法组(n=50),两组均接受戒烟热线电话咨询。主要结局为出院后12周持续戒烟,同时评估可行性、可接受性及7天时点戒烟率等次要结局。

要点

  • 这是首个在酒精或药物依赖人群中评估电子尼古丁装置戒烟效果与可接受性的随机对照试验。
  • 研究对象为无烟住宅戒断服务出院后的酒精或药物依赖者,共计划招募100人。
  • 主要结局为出院后12周持续戒烟,随访点为出院后6周和12周。

核心结论

  • 该试验旨在探索电子尼古丁装置相较于联合尼古丁替代疗法,在酒精或药物依赖者出院后戒烟中的有效性、可行性和可接受性。

研究设计与样本

  • 实用性随机对照试验,计划在澳大利亚墨尔本一家无烟住宅戒断服务机构招募100名参与者。
  • 参与者出院前随机分为电子尼古丁装置组(n=50)和联合尼古丁替代疗法组(n=50),两组均接受戒烟热线电话咨询支持。
  • 随访评估在出院后6周和12周进行,主要结局为出院后12周持续戒烟。

关键数值与推荐

  • 主要结局为出院后12周持续戒烟。
  • 次要结局包括7天时点戒烟率、所有尼古丁(含尼古丁替代疗法和电子尼古丁装置)时点戒断率、渴求与戒断症状、复发时间及治疗依从性。
  • 试验注册号:澳大利亚新西兰临床试验注册中心 ACTRN12617000849392,注册日期2017年6月8日。

临床怎么用

  • 该方案为在酒精或药物依赖治疗人群中整合新型戒烟支持提供了随机对照试验框架。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Up to 95% of people entering treatment for use of alcohol or other drugs (AOD) smoke tobacco. Smokers receiving treatment for AOD use are interested in quitting and make quit attempts, but relapse is more common and rapid compared with the general population of smokers. New ways to address smoking in this population are needed. Electronic nicotine devices (ENDs) or electronic cigarettes hold significant potential as both cessation aids and harm reduction support. This study focuses on the potential of ENDs to facilitate smoking cessation and to sustain it in the medium term among people in treatment for AOD use. The aim of this trial is to explore the effectiveness, feasibility and acceptability of ENDs for smoking cessation compared with combination nicotine replacement therapy (NRT) for clients after discharge from a smoke-free AOD residential withdrawal service. METHODS/DESIGN: The study is a pragmatic randomised controlled trial. In total, 100 participants will be recruited following admission to a smoke-free residential withdrawal service in Melbourne, Australia. Participants will complete a baseline survey and be randomised to either the END group (n = 50) or the NRT group (n = 50) prior to discharge. Both groups will receive telephone counselling support from quitline. Follow-up measures will be assessed at 6 and 12 weeks following discharge. The primary outcome is continuous abstinence from smoking at 12 weeks post discharge. Secondary outcomes include: 7-day point prevalence from smoking, point prevalence abstinence from all nicotine (including NRT and ENDs), cravings and withdrawal, time to relapse, and treatment adherence (use of NRT, ENDs and quitline). DISCUSSION: This is the first randomised controlled trial to assess the effectiveness and acceptability of ENDs within a population dependent on AOD, a priority group with very high levels of smoking. The research will test a model of how to incorporate novel smoking cessation support into a period of high treatment receptiveness. TRIAL REGISTRATION: Australian New Zealand Clinical Trial Registry, ACTRN12617000849392 . Registered on 8 June 2017.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Guillaumier A, Manning V, Wynne O, et al. Electronic nicotine devices to aid smoking cessation by alcohol- and drug-dependent clients: protocol for a pilot randomised controlled trial. Trials. 2018. PMID: 30071863. doi:10.1186/s13063-018-2786-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。